Under mounting pressure in diabetes, Eli Lilly has just become the latest drugmaker to undergo a major shakeup.
There is troubling news for Pfizer and cancer med Xtandi. Pfizer and partner Astellas have given up trials of Xtandi in breast cancer.
Corning, with input from Pfizer and Merck, intends to build a $500 million plant in the U.S. to produce a new pharma glass.
Bharat Biotech has initiated a phase 1 trial of its Chikungunya vaccine, while Themis started a phase 2 of its own candidate.
Bayer's Nexavar has had the first-line liver cancer space to itself for years, but Eisai is doing its best to change that.
The FDA actually invited Mitsubishi Tanabe to file Radicava for U.S. approval based on data generated in Japan. Now, it's the first new ALS med in decades.
Two months after snapping up Ariad, Takeda is getting a quick return. The Ariad-developed potential blockbuster Alunbrig won FDA approval Friday.
What could China's newly proposed foreign drug policy mean for multinational pharma companies, and how will it change the world’s second-largest pharma…
Johnson & Johnson has kept a positive attitude about its blockbuster immunology drug Remicade and the biosimilar competition it’s facing.
Takeda has finished enrolling 20,100 children for a massive phase 3 dengue vaccine study.